News and updates

Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal

May 21, 2019

PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 21 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today an agreement with Imegen (Valencia, Spain), for the exclusive distribution of the MammaPrint® and BluePrint® breast cancer genomic tests throughout Spain and Portugal. MammaPrint, which has extensive clinical validation, uses the proprietary,…

Read more

New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients With Poor Response To Anti-Estrogen Therapy Who May Benefit From Neoadjuvant Chemotherapy

April 24, 2019

PRESS RELEASE ER+ breast cancer patients reclassified as ER+ basal-type demonstrated significant response to chemotherapy underscoring critical role of advanced diagnostic tools Results published in Nature Publishing Group’s npj Breast Cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 24 April 2019 – Agendia, Inc., a world leader in precision oncology, today announced the publication of…

Read more

Agendia Announces Creation of New Center of Innovation and R&D Excellence

April 17, 2019

PRESS RELEASE Simultaneous creation of Global Lab Center of Excellence IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 17 April 2019 – Agendia, Inc., a world leader in precision oncology, announced today that it has created a new Center of Innovation and R&D Excellence in the Netherlands to leverage the considerable technical expertise and experience of…

Read more

Positive Assessment Issued for Agendia’s MammaPrint®

January 9, 2019

PRESS RELEASE Determination finds that Agendia’s MammaPrint® Breast Cancer Risk of Recurrence test improves net health outcome for patients and positions the test well for further adoption by health insurance plans in the U.S. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 9 January 2019 – Agendia, Inc., a world leader in precision oncology, announced today…

Read more